	Application No.	Applicant(s)
	Application No.	Applicant(s)
Notice of Allowability	10/527,044	CAMPBELL ET AL.
Notice of Allowability	Examiner	Art Unit
	Andrew B. Freistein	1626
The MAILING DATE of this communication appe All claims being allowable, PROSECUTION ON THE MERITS IS herewith (or previously mailed), a Notice of Allowance (PTOL-85) NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RI of the Office or upon petition by the applicant. See 37 CFR 1.313	(OR REMAINS) CLOSED in this ap or other appropriate communication GHTS. This application is subject to	plication. If not included will be mailed in due course. THIS
1. This communication is responsive to <u>Terminal Disclaimer 2/06/2006</u> .		
2. The allowed claim(s) is/are 1, 3-7, 11-12, 15-16, 22, and 26 (now 1-12).		
3. Acknowledgment is made of a claim for foreign priority un	nder 35 U.S.C. § 119(a)-(d) or (f).	
a) All b) Some* c) None of the:		
1. Certified copies of the priority documents have been received.		
2. Certified copies of the priority documents have been received in Application No		
3. Copies of the certified copies of the priority documents have been received in this national stage application from the		
International Bureau (PCT Rule 17.2(a)).		
* Certified copies not received:		
Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application. THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.		
4. A SUBSTITUTE OATH OR DECLARATION must be submit INFORMAL PATENT APPLICATION (PTO-152) which give		
5. CORRECTED DRAWINGS (as "replacement sheets") must be submitted.		
(a) I including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached		
1) hereto or 2) to Paper No./Mail Date		
(b) ☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date		
Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).		
6. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.		
Attachment(s)		
1. Notice of References Cited (PTO-892)		Patent Application (PTO-152)
2. Notice of Draftperson's Patent Drawing Review (PTO-948)	6. ⊠ Interview Summary Paper No./Mail Da	
3. Information Disclosure Statements (PTO-1449 or PTO/SB/0		
Paper No./Mail Date 12/29/2005 4. Examiner's Comment Regarding Requirement for Deposit	8. 🛛 Examiner's Stateme	ent of Reasons for Allowance
of Biological Material	9.	

Application/Control Number: 10/527,044

Art Unit: 1626

DETAILED ACTION

Claims 1, 3-7, 11, 12, 15, 16, 22, 26 and 29 are currently pending.

Claims 2, 8-10, 13, 14, 17-21, 23-25, 27 and 28 were cancelled.

Information Disclosure Statement

Applicant's information disclosure statement (IDS), filed on 12/29/2005, has been considered. Please refer to Applicant's copies of the 1449 submitted herewith.

Restriction Requirement

The restriction requirement is withdrawn. However, Applicant reserves the right to file divisional applications on non-elected subject matter.

Double Patenting

Claims 1, 8, 12, 13-16, 22 and 26 were provisionally rejected under the judicially created doctrine of obviousness-type double patenting over US Application No. 10/497,452 (sic). The rejections have been overcome by the filing of a terminal disclaimer on 2/06/2006 and are therefore withdrawn.

Claim Rejections - 35 USC § 112

Claims 15, 16, 22 and 26 were rejected under 35 USC 112, 1st paragraph. As a result of the amendment filed 1/24/06, which deleted "prevention" and "prophylactically effective amount," the rejection is withdrawn.

Examiner's Amendment

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided

Art Unit: 1626

by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given during a telephone interview with Attorney David Rubin on March 6, 2006.

This application has been amended as follows:

1. Cancel claim 29.

Reasons For Allowance

The instant invention is drawn to compounds of Formula (I),

$$\begin{array}{c|c}
X^1 & X^2 \\
\hline
 & X^5 & X^4
\end{array}$$

, pharmaceutical compositions comprising

compounds of Formula (I), and methods of treating pain comprising administering a compound of formula (I).

The closest relevant art is Nakatsuka et al, JP 2001-035664, which discloses the

compound

(see Nakatsuka et al., STN International (2005)

HCAPLUS Database, Accession No. 2001:98819, Reg. No. 324741-44-8). The compounds of the instant invention differ from Nakatsuka et al, because the phenyl group in the instant invention is substituted with n²-Y, wherein Y is heteroaryl, rather than a methyl group.

Application/Control Number: 10/527,044 Page 4

Art Unit: 1626

Telephone Inquiry

Any inquiry concerning this communication or earlier communications from the

examiner should be directed to Andrew B. Freistein whose telephone number is (571) 272-

8515. The examiner can normally be reached Monday-Friday, 8:30 am - 5:00 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's

supervisor, Joseph M^cKane can be reached on (571) 272-0699. The fax phone number for the

organization where this application or proceeding is assigned is (571) 273-8300.

Information regarding the status of an application may be obtained from the Patent

Application Information Retrieval (PAIR) system. Status information for published applications

may be obtained from either Private PAIR or Public PAIR. Status information for unpublished

applications is available through Private PAIR only. For more information about the PAIR

system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private

PAIR system, contact the Electronic Business Center (EBC) at (866) 217-9197 (toll-free).

Andrew B. Freistein Patent Examiner, AU 1626 Golam Shameem, Ph.D.

Primary Patent Examiner, AU 1626

Date: March 10, 2006

GOLAM M. M. SHAMEEM, PH.D. PRIMARY EXAMINER